GREY:ICOTF - Post by User
Comment by
FredZarfloonon Jun 20, 2018 1:59pm
73 Views
Post# 28200205
RE:Targeted Markets iCo-007 - Diabetes-Related Blindness ~$3B+.
RE:Targeted Markets iCo-007 - Diabetes-Related Blindness ~$3B+.ICO-007 was a bust.
https://www.clinicaltrials.gov/ct2/show/results/NCT01565148?term=ico-007&draw=1&rank=2 allain250 wrote: Targeted Markets iCo-007 - Diabetes-Related Blindness ~$3B+. iCo-007 may also have a potential for treatment of certain oncology indications, including ovarian cancer. 007 is nearing completion of Phase 1. Because of the nature of ongoing tests iCo has had hints of what might be seen in Phase Two trials, Confidence, as a result of early trials, is very high. The next step is to either partner develop the compound or raise sufficient capital to enter into Phase II trials.